Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 154

SpaceX IPO, Robotaxi Rules, and the Regulatory Wall Facing Elon Musk

Regulatory hurdles, rather than engineering challenges, are the main obstacles hindering the progress and success of Elon Musk’s companies, including SpaceX and Tesla.

## Questions to inspire discussion.

SpaceX Strategic Direction.

🚀 Q: Will SpaceX IPO due to defense contractor requirements? A: SpaceX’s expanding role as a defense contractor through projects like Star Shield increases IPO likelihood, as military requirements typically favor public companies for transparency and accountability according to Palmer Luckey.

🛰️ Q: How is SpaceX enabling freedom of information in restricted regions? A: Starlink has provided unfiltered internet access to Iranians since 2022 in coordination with the US government, successfully resisting signal jamming attempts and enabling freedom of information during protests.

💰 Q: What investment level is the space economy attracting in 2025? A: The space economy attracted $2.2 trillion in private investment in 2025, driven by SpaceX’s success, but viability of speculative models like space hotels and mining depends entirely on Starship’s cost and reliability.

Continue reading “SpaceX IPO, Robotaxi Rules, and the Regulatory Wall Facing Elon Musk” | >

Stem cells and adult neurogenesis

The brain has a remarkable ability to learn how to discriminate different stimuli. This video shows the work that is done within the LabEx Revive framework (www.revive.fr) in the laboratory directed by Prof. Pierre-Marie Lledo. Using mice and stem cells as a model, they have shown how adult neurogenesis is decreased or stimulated depending on different factors.

Learn more about this crucial area of stem cell research at: www.revive.fr, https://research.pasteur.fr/en/member… more about stem cells in general at www.eurostemcell.org.

Credits:
This video was made possible by the LabEx Revive (www.revive.fr), which is a selected project of the ANR \.

Johns Hopkins Scientists Identify Key Brain Protein That May Slow Alzheimer’s

Researchers at Johns Hopkins Medicine report that findings from a new study funded by the National Institutes of Health are helping to identify a promising new biological target for Alzheimer’s disease. The focus is a protein that produces a crucial gas within the brain.

Studies in genetically engineered mice show that the protein Cystathionine γ-lyase, also known as CSE, plays an essential role in forming memories, says Bindu Paul, M.S., Ph.D., an associate professor of pharmacology, psychiatry and neuroscience at the Johns Hopkins University School of Medicine who led the research. CSE is best known for generating hydrogen sulfide, the gas responsible for the smell of rotten eggs, but the new findings highlight its importance in brain function.

Mapping gene disruptions in sporadic early onset Alzheimer’s disease across key brain regions

A new study led by researchers at UTHealth Houston investigated both gene expression and regulation at single cell levels to reveal disruptions in gene function in three brain regions of patients with sporadic early onset Alzheimer’s disease.

The findings are published in Science Advances.

Only about 5% to 10% of patients with Alzheimer’s disease are younger than 65. Of those patients, 10% have mutations in the APP, PSEN1, and PSEN2 genes, which are associated with Alzheimer’s disease. The other 90% of these cases are classified as sporadic early onset Alzheimer’s, a rare and aggressive form of the disease that begins before age 65. The genetic tie in early onset Alzheimer’s is largely unidentified, representing a significant but understudied population.

Blood metabolite signature offers improved prediction of type 2 diabetes risk

Diabetes, a metabolic disease, is on the rise worldwide, and over 90% of cases are type 2 diabetes, where the body does not effectively respond to insulin.

Researchers from Mass General Brigham and Albert Einstein College of Medicine have identified metabolites (small molecules found in blood generated through metabolism) associated with the risk of developing type 2 diabetes in the future, and have revealed genetic and lifestyle factors that may influence these metabolites. They also developed a metabolomic signature that predicts future risk of type 2 diabetes beyond traditional risk factors.

Their results are published in Nature Medicine.

Combating Antimicrobial Resistance by Resensitising Bacteria to Antibiotics Using CRISPR: A Narrative Review

Background: Antimicrobial resistance (AMR) remains a formidable global health threat. Conventional strategy of developing new antibiotics is costly and unsustainable. Thus, innovative approaches for resensitising bacteria using clustered regularly inter-spaced short palindromic repeats (CRISPR) technology are sought.

Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States

Background and ObjectivesAs evidence supporting the robustness of blood-based biomarker (BBM) testing for Alzheimer disease (AD) continues to emerge, understanding the perceptions, drivers, and barriers to the adoption of these tests among primary care…

Use of Ictal-Interictal SPECT in Localization of Surface-EEG–Negative Insular Epilepsy

This case demonstrates the use of ictal SPECT as an objective way to localize surface-EEG–negative insular seizures.

A 43-year-old woman presented with events characterized by a “funny” feeling in the head, nausea, and right-hand numbness/cramping. Events lasted minutes, without impaired awareness. Onset occurred 1.5 years after an embolic left middle cerebral artery stroke. MRI showed left temporoparietal and insular T2 changes.

Synchrotron‐generated microbeams as a radiosurgical alternative for drug‐resistant epilepsies: Proof of concept in a mouse model of mesiotemporal lobe epilepsy

“This proof-of-concept study highlights MRT as a promising non-invasive therapy for drug-resistant focal epilepsies with optimal peak doses of 125–250 Gy, and it suggests that distributing the dose through multiple angles optimizes the therapeutic effect. MRT could provide a safer alternative to surgery, warranting further investigations.”

Read this open-access research article from Epilepsia Journal at doi.org/10.1002/epi.70063.

Objective One-third of patients with epilepsy, particularly those with mesial temporal lobe epilepsy (MTLE), remain resistant to medication. Resective surgery, the gold standard, is highly invasive and carries significant risks. Here, using a mouse model, we explored the potential of microbeam radiation therapy (MRT), a new technique based on the spatial microfractionation of high-flux X-rays, as a non-invasive alternative for treating MTLE.

Cyanobacteria can utilize toxic guanidine as a nitrogen source

Guanidine is an organic compound primarily used as a denaturing reagent to disrupt the structures of proteins and nucleic acids. Together with partner institutions, scientists at the Helmholtz Centre for Environmental Research (UFZ) have demonstrated that cyanobacteria, which play a central role in global biogeochemical cycles, use guanidine as a nitrogen source.

The results were recently published in the Proceedings of the National Academy of Sciences. The researchers shed light on the underlying mechanisms and the potential for a new tool for sustainable biotechnological applications.

/* */